Avicanna Inc. (AVCNF)
OTCMKTS · Delayed Price · Currency is USD
0.1900
-0.0100 (-5.00%)
Oct 24, 2025, 9:37 AM EDT
Avicanna Revenue
Avicanna had revenue of 6.16M CAD in the quarter ending June 30, 2025, with 0.56% growth. This brings the company's revenue in the last twelve months to 25.37M, up 2.00% year-over-year. In the year 2024, Avicanna had annual revenue of 25.46M with 51.62% growth.
Revenue (ttm)
25.37M CAD
Revenue Growth
+2.00%
P/S Ratio
1.22
Revenue / Employee
291.64K CAD
Employees
87
Market Cap
22.70M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25.46M | 8.67M | 51.62% |
| Dec 31, 2023 | 16.79M | 12.74M | 314.82% |
| Dec 31, 2022 | 4.05M | 778.98K | 23.83% |
| Dec 31, 2021 | 3.27M | 1.70M | 108.20% |
| Dec 31, 2020 | 1.57M | 1.40M | 833.16% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 1.95M |
| Northwest Biotherapeutics | 1.09M |
Avicanna News
- 6 weeks ago - Avicanna Announces Change in CFO - GlobeNewsWire
- 7 weeks ago - Avicanna Subsidiary Completes Export of CBD Dominant Cannabis Flower into Switzerland - GlobeNewsWire
- 7 weeks ago - Avicanna LATAM SAS Teams Up With Harrington Wellness to Launch re+PLAY CBD Wellness Brand Topicals in the United States - GlobeNewsWire
- 2 months ago - Avicanna Reports Q2 2025 - GlobeNewsWire
- 2 months ago - Avicanna Announces US Patent and Trademark Office Issuance of New Patent - GlobeNewsWire
- 3 months ago - Avicanna Announces Closing of Non-Brokered Private Placement - GlobeNewsWire
- 4 months ago - Avicanna Announces Results of Annual General Meeting - GlobeNewsWire
- 5 months ago - Avicanna Announces Sponsorship of Pilot Phase II Clinical Study Osteoarthritis Pain - GlobeNewsWire